Skip to content

Salvage therapy: new protease inhibitors promising

Hepatitis B and C increase risk of liver toxicity after starting HAART

Nevirapine use in PEP: concerns over rash

Australian HIV vaccine shows promise

Another drug bites the dust: Glaxo-Wellcome drop NNRTI

Disappointing amprenavir results: only 30% undetectable at 48 weeks

Male breast enlargement seen with all drug classes

Therapeutic drug monitoring: quality control still needed, international study shows

UK trial finds no diffference in failure rates of thicker versus standard condoms for gay men